Published in Women's Health Weekly, December 4th, 2003
Linda Grable, CEO, stated, "With this agreement, IDSI is addressing a new market, targeting pharmaceutical developers and researchers who monitor cancer growth. It is exciting and beneficial to be adding a new product line to complement our CTLM breast imaging product. This work draws on the 9 years of R&D at Imaging Diagnostics in the optical imaging field, particularly drawing on the fluorescence work we have done at the University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.